Physiologically Based Pharmacokinetic Modeling to Predict Lamotrigine Exposure in Special Populations to Facilitate Therapeutic Drug Monitoring and Guide Dosing Regimens
Pharmaceuticals · 27.04.2025 · 18 (5) · 637
DOI: 10.3390/ph18050637 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 27.04.2025. Verfasst von Ji-Cheng Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, The School of Pharmacy, F…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
Background
Lamotrigine plays a crucial role in the treatment of epilepsy and bipolar disorder in adults and children. However, its pharmacokinetic (PK) behavior in first or long-term treatment in pediatric patients and the changes in drug exposure in patients with renal impairment are not well characterized. The purpose of the research was to build a robust physiologically based pharmacokinetic (PBPK) model of lamotrigine for the prediction of drug exposure in diverse populations to facilitate therapeutic drug monitoring (TDM) and guide dosing regimens.
Methods
The physicochemical parameter values of lamotrigine were integrated to establish and validate the model in an adult population in PK-sim. This adult PBPK model can be extrapolated to children and patients with renal impairment to predict PK changes.
Results
Most of the observed data were within the 5th and 95th percentile intervals of the variability around the predicted plasma concentrations. The model predicted pharmacokinetic thresholds and exposure values for clinically safe and effective doses recommended by the FDA for initial and long-term treatment of epilepsy in adults and children aged 2–12 years. Notably, patients with severe renal impairment and end-stage renal disease experienced an average increase in the area under the curve of 1.51 folds and 1.62 folds, respectively. This scenario necessitates further lamotrigine dose adjustments.
Conclusions
The developed lamotrigine PBPK model offers a strategy for assisting clinicians in TDM and dose adjustment for special populations, thereby offering a reference (PK parameters, as well as peak and valley concentrations to reach a steady state) for a safer administration regimen in clinical treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, The School of Pharmacy, Fujian Medical University, Fuzhou 350122, China.
ORCID-Profile: Ji-Cheng Li, Ai-Lin Liu
Förderung
- National Natural Science Foundation of China
- Innovation of Science and Technology, Fujian Province
Zitieren
APA
Li, J. C., Miao, C. F., Lei, Y., & Liu, A. L. (2025). Physiologically Based Pharmacokinetic Modeling to Predict Lamotrigine Exposure in Special Populations to Facilitate Therapeutic Drug Monitoring and Guide Dosing Regimens. Pharmaceuticals, 18(5), 637. https://doi.org/10.3390/ph18050637
Vancouver
Li JC, Miao CF, Lei Y, Liu AL. Physiologically Based Pharmacokinetic Modeling to Predict Lamotrigine Exposure in Special Populations to Facilitate Therapeutic Drug Monitoring and Guide Dosing Regimens. Pharmaceuticals. 2025;18(5):637. doi:10.3390/ph18050637
BibTeX
@article{Li2025,
author = {Li, Ji-Cheng and Miao, Chen-Fang and Lei, Yun and Liu, Ai-Lin},
title = {Physiologically Based Pharmacokinetic Modeling to Predict Lamotrigine Exposure in Special Populations to Facilitate Therapeutic Drug Monitoring and Guide Dosing Regimens},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {5},
pages = {637},
doi = {10.3390/ph18050637}
}
EUVIMED